To include your compound in the COVID-19 Resource Center, submit it here.

Intercept reports patient death in Phase II NASH trial of Ocaliva

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) reported a patient death in the long-term extension of the Phase II CONTROL trial of Ocaliva obeticholic acid (DSP-1747) to treat non-alcoholic steatohepatitis (NASH) patients with fibrosis and compensated cirrhosis. The patient died due to acute renal and liver failure, according

Read the full 450 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE